SlidesetViral Hepatitis and Liver DiseasePotential of new combinations to achieve functional cure for Chronic Hepatitis B - Fabien Zoulim, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRationale for including immune tolerant and low viral load patients in new drug trials placeholder - Henry Lik Yeun ChanView Slideset
SlidesetViral Hepatitis and Liver DiseaseHow to interpret flares in HBV trials with novel agents - Pietro Lampertico, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseToxicity in new and established HBV compounds - Jordan Feld, MD, MPHView Slideset
SlidesetViral Hepatitis and Liver DiseaseSafety Monitoring for Investigational HBV Drugs and Discontinuation of HBV Therapy - Poonam Mishra MD, MPH, FAASLDView Slideset
SlidesetViral Hepatitis and Liver DiseaseUpdate on Hepatitis Delta Therapy - Robert Gish MD, FAASLD, AGAF, FASTView Slideset
SlidesetViral Hepatitis and Liver DiseaseUpdate on New Antiviral Targets –non –Capsid Inhibitors - Man-Fung YuenMBBS, MD, PhD, DScView Slideset
SlidesetViral Hepatitis and Liver DiseaseUpdate on New Immuno Modulators - Adam Gehring PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseUpdate on Novel Combination Strategies - Marion Peters MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseUpdate on New Antiviral Targets Core Capsid Inhibitors (CpAMs) - Kosh Agarwal BMedSci (Hons) MD FRCPView Slideset
